Metraipolis › archive › dc_617d28ecea10
Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study — Europe PMC PMID:41929598
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41929598
- DOI
- 10.3389/fneur.2026.1783506
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-04T07:41:39.109Z
- SHA-256 of the archived text
ac975dbdeb9163cdf1e265b81c2ddd2165750166d380742bd9ed22626dece4f2- Stable URL of this page
https://metraipolis.com/documento/dc_617d28ecea10
How to cite
Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study — Europe PMC PMID:41929598 — Europe PMC (en), https://europepmc.org/article/MED/41929598 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_617d28ecea10 (Metraipolis archive dc_617d28ecea10, sha256 ac975dbdeb9163cdf1e265b81c2ddd2165750166d380742bd9ed22626dece4f2)
BibTeX
@misc{dc617d28ecea10,
title = {Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study — Europe PMC PMID:41929598},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41929598},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_617d28ecea10; sha256 ac975dbdeb9163cdf1e265b81c2ddd2165750166d380742bd9ed22626dece4f2},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41929598. Agents can read the archived copy with the MCP tool read_document.